Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...

Immune-check point inhibitors used in chemotherapy have an increased risk of noninfectious uveitis (inflammation of the eye wall) and myasthenia gravis (MG). People who use immune-check point ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every ...

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

Purpose Myasthenia gravis can cause variable strabismus with disabling diplopia and/or poor cosmesis. A retrospective study of a group of patients with myasthenia gravis or ‘myasthenia gravis like’ ...

DUBLIN--(BUSINESS WIRE)--The "Ophthalmology Pipeline Database - 2018" report has been added to ResearchAndMarkets.com's offering. Ophthalmology Pipeline Highlights Database - 2018, provides most up-to ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...

Myasthenia gravis is a chronic autoimmune disorder that inhibits communication between nerve cells and muscles, causing muscle weakness. It has no cure, but several treatment options can help improve ...

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...

Myasthenia gravis is an autoimmune disease that affects the transmission of signals from nerves to muscles. The name myasthenia gravis comes from Greek and Latin words meaning "grave muscle weakness." ...